Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1-induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.

中文翻译：

---

APOL1 肾病治疗是否一直隐藏在众目睽睽之下？


APOL1 的两种编码变体是近期西非血统人群局灶节段性肾小球硬化风险的大部分原因。载脂蛋白 L1 肾病的治疗需求未得到满足。在本期中，Sula Karreci 等人报道了赖诺普利以基因型特异性方式减少了载脂蛋白 L1 诱导的局灶节段性肾小球硬化小鼠模型中的蛋白尿和肾小球硬化。相比之下，肼屈嗪和达格列净没有效果。本研究强调了血管紧张素转换酶抑制剂在载脂蛋白 L1 肾病中的潜在治疗效用。